Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study
The goal of this observational study is to collect information on the long-term safety of study participants who received an Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Product in an Imugene Clinical Study. The main questions it aims to answer are:
- What are the frequency, severity, duration, and outcome of clinically significant Clinical Events of Interest (CEI)?
- What is the duration of response and overall survival time after taking an allogeneic CAR T-Cell product on an Imugene clinical study?
Participants will have a yearly visit either face to face or remotely for up to 15 years to check for CEI.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Imugene Limited
- Phone Number: 1 984 245 0082
- Email: info@imugene.com
Study Locations
-
-
California
-
Culver City, California, United States, 90230
- Recruiting
- Science 37, Inc.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Receipt of at least 1 dose of azer-cel in an Imugene clinical study.
- A signed informed consent form (ICF).
- Willingness and ability to adhere to the study schedule and all other protocol requirements.
Exclusion Criteria:
- No unique exclusion criteria apply to this study.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Frequency of Clinically Significant Clinical Events of Interest (CEI)
Time Frame: Up to 15 years
|
Up to 15 years
|
|
Severity of Clinically Significant CEI
Time Frame: Up to 15 years
|
Up to 15 years
|
|
Duration of Clinically Significant CEI
Time Frame: Up to 15 years
|
Up to 15 years
|
|
Outcome of Clinically Significant CEI
Time Frame: Up to 15 years
|
Up to 15 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Duration of Disease Response
Time Frame: Up to 15 years
|
Up to 15 years
|
|
Overall Survival Rate
Time Frame: Up to 15 years
|
Up to 15 years
|
|
Azer-cel Persistence
Time Frame: Up to 15 years
|
Up to 15 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- PBCAR-LTF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.